alexa New Insights into the “Obesity Paradox” and Cardiovascular Outcomes | OMICS International
ISSN: 2153-0637
Journal of Glycomics & Lipidomics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

New Insights into the “Obesity Paradox” and Cardiovascular Outcomes

Carl J. Lavie1,2*, Alban De Schutter1,4, Dharmendrakumar A. Patel1, Timothy S. Church2, Ross Arena3, Abel Romero-Corral5, Paul McAuley6, Hector O. Ventura1 and Richard V. Milani1

1Department of Cardiovascular Diseases, John Ochsner Heart & Vascular Institute Ochsner Clinical School-The University of Queensland School of Medicine New Orleans, LA, USA

2Department of Preventive Medicine, Pennington Biomedical Research Center Baton Rouge, LA, USA

3Physical Therapy Program-Department of Orthopaedics and Rehabilitation and Division of Cardiology-Department of Internal Medicine University of New Mexico Health Sciences Center Albuquerque, NM, USA

4Department of Internal Medicine, Cleveland Clinic Florida Weston, FL, USA

5Einstein Institute for Heart and Vascular Health, Einstein Medical Center Philadelphia, PA, USA

6Human Performance and Sport Sciences, Winston-Salem State University, Winston-Salem, NC, USA

*Corresponding Author:
Carl J. Lavie, MD
FACC, FACP, FCCP, Medical Director
Cardiac Rehabilitation Director
Exercise Laboratories John Ochsner Heart and Vascular Institute Ochsner Clinical School - The University of Queensland School of Medicine
1514 Jefferson Highway, New Orleans
LA 70121-2483, USA
Tel: (504) 842-5874
Fax: (504) 842-5875
E-mail: [email protected]

Received date: July 12, 2012; Accepted date: July 13, 2012; Published date: July 16, 2012

Citation: Lavie CJ, Schutter AD, Patel DA, Church TS, Arena R, et al. (2012) New Insights into the “Obesity Paradox” and Cardiovascular Outcomes. J Glycomics Lipidomics 2:e106. doi: 10.4172/2153-0637.1000e106

Copyright: © 2012 Lavie CJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Glycomics & Lipidomics

Introduction

Overweight and obesity are increasing in epidemic proportions both in the United States (US) and throughout the Western World [1]. A considerable burden from cardiovascular disease (CVD) in the US has been “heavily” impacted by the obesity epidemic, with the current estimation of obesity prevalence in US children and adolescents being just under 20%, with a prevalence >33% in adults 24-74 years of age [2]. Alarmingly, the proportion of patients with either severe or morbid obesity is increasing even more so than are overweight and obesity per se [1]. Almost all of the major CVD risk factors, including glucose abnormalities (impaired fasting glucose, metabolic syndrome, and type 2 diabetes mellitus), lipid disorders (especially elevated levels of triglycerides and low levels of high-density lipoprotein cholesterol), hypertension (HTN) and left ventricular hypertrophy, and physical inactivity ,as well as sleep apnea, are all adversely impacted by overweight and obesity [1,3-5]. In addition, overweight and obesity may be independent risk factors for coronary heart disease (CHD) and have adverse impacts on almost all CVD, including HTN, heart failure (HF), atrial fibrillation (AF), and sudden cardiac death [1,3-5].

Despite the powerful impact, however, that overweight and obesity have on CHD risk factors, CHD, and other CVD, numerous studies and meta-analyses have addressed the “obesity paradox,” which indicates that once CVD becomes established, including CHD, HF, HTN, and AF, overweight and obese have a better prognosis than do their lean counterparts with the same CVD [1,3-7]. The obesity paradox has been discounted by some experts who have suggested that this may be due to such factors as sample size errors or by unmeasured confounding factors, as was also suggested in a recent major study of in-hospital mortality in acute myocardial infarction [3,8,9]. However, even very large meta-analyses have demonstrated this paradox in CHD and HF [6,7]. In fact, Romero-Corral and colleagues [6] evaluated 40 studies of more than 250,000 patients with CHD and demonstrated that in patients grouped according to body mass index (BMI), those in the lowest or “normal” BMI group had the highest all-cause mortality, whereas better survival was observed in higher BMI groups. The overweight had the lowest relative risk, whereas obesity and severe obesity have no increased mortality risk. Likewise, in HF, Oreopoulos and colleagues [7] reviewed 29,000 patients from 9 major HF studies and demonstrated reductions in CV and total mortality of 19% and 16%, respectively in the overweight and 40% and 33%, respectively in the obese compared with normal-weight patients with HF.

Many have blamed the obesity paradox on relatively poor accuracy of BMI to reflect true body fatness, and we agree that other measures of body composition [including waist circumference (WC), waist-tohip ratio, and measures of visceral and peripheral adiposity] may all be superior to BMI in the assessment of body fatness [1,3-6,10-15]. We have demonstrated the obesity paradox, however, in both HF [14,16] and CHD [13,15,17-19] with both BMI and percent body fat (BF), demonstrating that BF was an independent predictor of better eventfree survival. In CHD, we have demonstrated that low BF (≤ 25% in men and ≤ 35% in women) predicted a nearly three-fold increase in mortality compared with high BF [10,12,14]; also, we demonstrated that the combination of low BF and low BMI (< 25 kg/m2) [13] and, particularly, low BF and low lean body mass [15] was associated with the worst survival in stable CHD. In HF, for every one percent increase in BF, there was a 13% increase in event-free survival [16].

Interestingly, the data regarding central obesity/WC and the obesity paradox has been mixed [19-25]. Several recent studies in CHD have indicated that central obesity was associated with mortality in patients with both “normal” BMIs as well as an overweight/obese BMIs [20,21], and this was also noted in end-stage renal disease [22]. However, another recent CHD paper from me and my colleagues in a very large cohort demonstrated that the obesity paradox was present even in those with central obesity (high WC), at least in those with low levels of cardiorespiratory fitness (CRF; discussed below) [19]. Another recent study in HF indicates that a high WC was an independent predictor of better event-free survival, with the best survival occurring in those with both a high WC and high BMI [23,24], and preliminary data from our Ochsner group suggest the same for CHD [25].

The reasons for the obesity paradox have been difficult to decipher. Certainly, none of the major studies or meta-analyses have been able to account for the possibility of non-purposeful weight loss prior to study entry, which clearly would be expected to be associated with poor survival [1,3-5,14,24]. Overweight and obesity have lower expression of brain natriuretic peptide, which may cause obese patients with HF to present earlier due to increased symptoms at an earlier stage of disease [26], but this mechanism would hardly explain the obesity paradox in stable patients with CHD or HTN or in those referred for exercise stress testing or echocardiographic assessment (even with normal left ventricular systolic function) [1,3-5,14,18,24,27-29]. Overweight and obese may also develop symptoms/signs, such as dyspnea and peripheral edema that mimic those of CVD but are instead due to deconditioning, restrictive lung disease, and venous insufficiency, but nevertheless lead to an earlier presentation with milder disease [30]. Additionally, overweight/obese may also have lower plasma renin activity and higher levels of arterial pressure, allowing these patients to tolerate more proven medications at higher doses than do leaner patients with CVD [1]. Confounding factors, such as less smoking and lower age, could partly impact the obesity paradox, but this paradox is still present when these factors are adequately accounted for in multivariate analyses [13,15,31-33]. Quite possibly, overweight and obese patients who develop CVD may have avoided CVD in the first place had significant weight gain during adulthood been prevented, whereas the lean patients who develop the same CVD do so for other reasons, such as genetic predisposition, which could be associated with a worse prognosis [3-5, 24].

So far, however, one confounding factor that has been consistent is the impact of CRF on the obesity paradox. In four separate studies of cohorts with CHD, overweight/obese with high CRF have a low mortality and there does not appear to be an obesity paradox, whereas the obesity paradox is present in those with low levels of CRF [18- 20,34]. preliminary data from a large multicenter study in HF suggest the same [35]. Importantly, CRF appears to significantly impact the relationship between adiposity and subsequent CVD and mortality risk in both CHD and HF. Therefore, assessing adiposity without understanding CRF may be misleading, since CRF markedly influences the importance of body composition on CVD prognosis.

In conclusion, overweight and obesity worsen almost all of the CVD risk factors and are associated with a high prevalence of almost all major CVD, including CHD, HF, HTN and AF. Despite these factors, an obesity paradox exists, in that overweight/obese with established CVD have an overall favorable prognosis, even more so than do their lean counterparts with the same CVD. Nevertheless, the overall “weight” of evidence all supports purposeful weight reduction for overweight/ obese, for both the primary and secondary prevention of CVD [1,3- 5,24,36-38]. However, randomized controlled clinical trials of varying intensity of exercise training (to improve both CRF and muscular strength) [39] and weight reduction (including the newer weight loss medications) [1,3-5,24,36-38] are clearly needed to evaluate the impact of purposeful weight loss, especially in secondary prevention of CVD.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 3rd International Conference on Enzymology and Molecular Biology March 05-06, 2018 London, UK
    March 05-06, 2018 London, UK
  • 3rd International Conference on Biochemistry & Molecular Biology May 16-17, 2018 Singapore Theme: Novel Advancements in Biochemistry & Molecular Biology
    May 16-17, 2018 Singapore City, Singapore
  • World Congress on Bio-organic and Medicinal Chemistry July 19-21, 2018 Dubai, UAE
    July 19-21, 2018 Dubai, UAE
  • International Conference on Computational Biology and Bioinformatics Sep 05-06 2018 Tokyo, Japan
    November 19-21-2018 Bucharest, Romania
  • 3rd International Conference on Enzymology and Molecular Biology
    September 17-18, 2018 Singapore City, Singapore
  • 4th International Conference on Enzymology and Lipid Science September 17-18, 2018 Singapore Theme: Novel Advancements in Enzymology and Lipid Science
    September 17-18, 2018 Singapore City, Singapore
  • 4th International Conference on Biochemistry & Biophysics October 03-04, 2018 Los Angeles, California, USA
    October 03-04, 2018 Los Angeles, USA
  • 9th International Conference on Biopolymers and Polymer Sciences November 19-21-2018 Romania,Bucharest
    November 19-21-2018 Bucharest, Romania
  • 12th International Conference on Advancements in Bioinformatics and Drug Discovery
    November 26-27, 2018 Dublin, Ireland
  • Cellular and Molecular Mechanism Conference: Health and Disease November 29-30, 2018 Bali, Indonesia
    November 19-21-2018 Bucharest, Romania

Article Usage

  • Total views: 11613
  • [From(publication date):
    July-2012 - Feb 25, 2018]
  • Breakdown by view type
  • HTML page views : 7851
  • PDF downloads : 3762
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version